CGL
SYRS

Clarius Group LLC’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Clarius Group LLC’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-18,620
Closed -$4.28K – 505
2024
Q4 		$4.28K Hold
18,620
– – ﹤0.01% 452
2024
Q3 		$40K Hold
18,620
– – ﹤0.01% 452
2024
Q2 		$96.1K Hold
18,620
– – 0.01% 436
2024
Q1 		$99.6K Hold
18,620
– – 0.01% 474
2023
Q4 		$145K Hold
18,620
– – 0.01% 463
2023
Q3 		$73.5K Buy
+18,620
New +$69.7K 0.01% 451
2023
Q2 		– Sell
-18,620
Closed -$49.7K – 524
2023
Q1 		$49.7K Hold
18,620
– – ﹤0.01% 502
2022
Q4 		$67K Sell
18,620
-727
-4% -$3.15K 0.01% 501
2022
Q3 		$125K Sell
19,347
-1
-0% -$8 0.01% 470
2022
Q2 		$186K Buy
+19,348
New +$181K 0.02% 448

Other funds holding SYRS

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
1CM
1492 Capital Management Milwaukee, Wisconsin $263M AUM 61.9% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Clarius Group LLC's SYRS Position: Q1 2025 in Review

Clarius Group LLC sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2025, closing a stake of 18,620 shares — an estimated $4.28K sold.

Clarius Group LLC first reported a position in SYRS in Q2 2022 and held it in 10 quarters. The position peaked at $186K in Q2 2022. 7 funds tracked by Wall St. Rank hold SYRS as of Q1 2025.

  • Clarius Group LLC reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Clarius Group LLC sold 18,620 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2025, an estimated $4.28K.
  • Clarius Group LLC first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2022 and held it in 10 quarters.
  • Clarius Group LLC's Syros Pharmaceuticals, Inc. Common Stock position peaked at $186K in Q2 2022.
  • 7 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2025.

Based on Clarius Group LLC's 13F filing for Q1 2025, filed 18 Apr 2025.